Psoriasis Drugs Market Research Report: By Type (Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies), Mechanism of Action (Tumor Necrosis Factor-Alpha Inhibitors, Phosphodiesterase Type 4 Inhibitors, Interleukin Inhibitors), Route of Administration (Oral, Parenteral, Topical) - Global Industry Analysis and Demand Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Analysis Period

1.4 Market Data Reporting Unit

1.4.1 Value

1.5 Market Size Breakdown by Segment

1.5.1 Market Segmentation by Type

1.5.2 Market Segmentation by Mechanism of Action (MoA)

1.5.3 Market Segmentation by Route of Administration (RoA)

1.5.4 Market Segmentation by Region

1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Paid

2.1.2 Unpaid

2.1.3 P&S Intelligence Database

2.2 Primary Research

2.2.1 Breakdown of Primary Research, by Region

2.2.2 Breakdown of Primary Research, by Industry Participant

2.2.3 Breakdown of Primary Research, by Company Type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

5.1 Dermatology Drugs Market – The Parent Market

Chapter 6. Definition of Market Segments

6.1 By Type

6.1.1 Biologic Drugs

6.1.2 Small-Molecule Systemic Drugs

6.1.3 Topical Therapies

6.2 By MoA

6.2.1 TNF-Alpha Inhibitors

6.2.2 PDE4 Inhibitors

6.2.3 Interleukin Inhibitors

6.2.4 Others

6.3 By RoA

6.3.1 Oral

6.3.2 Parenteral

6.3.3 Topical

Chapter 7. Industry Outlook

7.1 Market Dynamics

7.1.1 Trends

7.1.1.1 Increasing number of product approvals

7.1.2 Drivers

7.1.2.1 Rising geriatric population

7.1.2.2 Increasing prevalence of psoriasis

7.1.2.3 Growing awareness about psoriasis

7.1.2.4 Extensive pipeline of psoriasis drugs

7.1.2.5 Impact analysis of drivers on market forecast

7.1.3 Restraints

7.1.3.1 Patent expiry of some popular drugs

7.1.3.2 Side-effects of certain classes of therapeutic drugs

7.1.3.3 Impact analysis of restraints on market forecast

7.1.4 Opportunities

7.1.4.1 Huge potential in emerging markets

7.2 Impact of COVID-19

7.2.1 Porter’s Five Forces Analysis

Chapter 8. Global Market Size and Forecast

8.1 Overview

8.2 Market Revenue, by Type (2025–2030)

8.3 Market Revenue, by MoA (2025–2030)

8.4 Market Revenue, by RoA (2025–2030)

8.5 Market Revenue, by Region (2025–2030)

Chapter 9. North America Market Size and Forecast

9.1 Overview

9.2 Market Revenue, by Type (2025–2030)

9.3 Market Revenue, by MoA (2025–2030)

9.4 Market Revenue, by RoA (2025–2030)

9.5 Market Revenue, by Country (2025–2030)

Chapter 10. Europe Market Size and Forecast

10.1 Overview

10.2 Market Revenue, by Type (2025–2030)

10.3 Market Revenue, by MoA (2025–2030)

10.4 Market Revenue, by RoA (2025–2030)

10.5 Market Revenue, by Country (2025–2030)

Chapter 11. APAC Market Size and Forecast

11.1 Overview

11.2 Market Revenue, by Type (2025–2030)

11.3 Market Revenue, by MoA (2025–2030)

11.4 Market Revenue, by RoA (2025–2030)

11.5 Market Revenue, by Country (2025–2030)

Chapter 12. LATAM Market Size and Forecast

12.1 Overview

12.2 Market Revenue, by Type (2025–2030)

12.3 Market Revenue, by MoA (2025–2030)

12.4 Market Revenue, by RoA (2025–2030)

12.5 Market Revenue, by Country (2025–2030)

Chapter 13. MEA Market Size and Forecast

13.1 Overview

13.2 Market Revenue, by Type (2025–2030)

13.3 Market Revenue, by MoA (2025–2030)

13.4 Market Revenue, by RoA (2025–2030)

13.5 Market Revenue, by Country (2025–2030)

Chapter 14. U.S. Market Size and Forecast

14.1 Overview

14.2 Market Revenue, by Type (2025–2030)

14.3 Market Revenue, by MoA (2025–2030)

14.4 Market Revenue, by RoA (2025–2030)

Chapter 15. Canada Market Size and Forecast

15.1 Overview

15.2 Market Revenue, by Type (2025–2030)

15.3 Market Revenue, by MoA (2025–2030)

15.4 Market Revenue, by RoA (2025–2030)

Chapter 16. Germany Market Size and Forecast

16.1 Overview

16.2 Market Revenue, by Type (2025–2030)

16.3 Market Revenue, by MoA (2025–2030)

16.4 Market Revenue, by RoA (2025–2030)

Chapter 17. France Market Size and Forecast

17.1 Overview

17.2 Market Revenue, by Type (2025–2030)

17.3 Market Revenue, by MoA (2025–2030)

17.4 Market Revenue, by RoA (2025–2030)

Chapter 18. U.K. Market Size and Forecast

18.1 Overview

18.2 Market Revenue, by Type (2025–2030)

18.3 Market Revenue, by MoA (2025–2030)

18.4 Market Revenue, by RoA (2025–2030)

Chapter 19. Italy Market Size and Forecast

19.1 Overview

19.2 Market Revenue, by Type (2025–2030)

19.3 Market Revenue, by MoA (2025–2030)

19.4 Market Revenue, by RoA (2025–2030)

Chapter 20. Spain Market Size and Forecast

20.1 Overview

20.2 Market Revenue, by Type (2025–2030)

20.3 Market Revenue, by MoA (2025–2030)

20.4 Market Revenue, by RoA (2025–2030)

Chapter 21. Japan Market Size and Forecast

21.1 Overview

21.2 Market Revenue, by Type (2025–2030)

21.3 Market Revenue, by MoA (2025–2030)

21.4 Market Revenue, by RoA (2025–2030)

Chapter 22. China Market Size and Forecast

22.1 Overview

22.2 Market Revenue, by Type (2025–2030)

22.3 Market Revenue, by MoA (2025–2030)

22.4 Market Revenue, by RoA (2025–2030)

Chapter 23. India Market Size and Forecast

23.1 Overview

23.2 Market Revenue, by Type (2025–2030)

23.3 Market Revenue, by MoA (2025–2030)

23.4 Market Revenue, by RoA (2025–2030)

Chapter 24. Australia Market Size and Forecast

24.1 Overview

24.2 Market Revenue, by Type (2025–2030)

24.3 Market Revenue, by MoA (2025–2030)

24.4 Market Revenue, by RoA (2025–2030)

Chapter 25. South Korea Market Size and Forecast

25.1 Overview

25.2 Market Revenue, by Type (2025–2030)

25.3 Market Revenue, by MoA (2025–2030)

25.4 Market Revenue, by RoA (2025–2030)

Chapter 26. Brazil Market Size and Forecast

26.1 Overview

26.2 Market Revenue, by Type (2025–2030)

26.3 Market Revenue, by MoA (2025–2030)

26.4 Market Revenue, by RoA (2025–2030)

Chapter 27. Mexico Market Size and Forecast

27.1 Overview

27.2 Market Revenue, by Type (2025–2030)

27.3 Market Revenue, by MoA (2025–2030)

27.4 Market Revenue, by RoA (2025–2030)

Chapter 28. Saudi Arabia Market Size and Forecast

28.1 Overview

28.2 Market Revenue, by Type (2025–2030)

28.3 Market Revenue, by MoA (2025–2030)

28.4 Market Revenue, by RoA (2025–2030)

Chapter 29. South Africa Market Size and Forecast

29.1 Overview

29.2 Market Revenue, by Type (2025–2030)

29.3 Market Revenue, by MoA (2025–2030)

29.4 Market Revenue, by RoA (2025–2030)

Chapter 30. Competitive Landscape

30.1 List of Major Drugs and Their Manufacturers

30.2 Recent Strategic Developments of Key Players

30.2.1 Product Launches and Approvals

30.2.2 Acquisitions

30.2.3 Other Developments

Chapter 31. Company Profiles

31.1 Novartis AG

31.1.1 Business Overview

31.1.2 Product and Service Offerings

31.1.3 Key Financial Summary

31.2 Pfizer Inc.

31.2.1 Business Overview

31.2.2 Product and Service Offerings

31.2.3 Key Financial Summary

31.3 Bristol-Myers Squibb Company

31.3.1 Business Overview

31.3.2 Product and Service Offerings

31.3.3 Key Financial Summary

31.4 Johnson & Johnson

31.4.1 Business Overview

31.4.2 Product and Service Offerings

31.4.3 Key Financial Summary

31.5 Merck & Co. Inc.

31.5.1 Business Overview

31.5.2 Product and Service Offerings

31.5.3 Key Financial Summary

31.6 AbbVie Inc.

31.6.1 Business Overview

31.6.2 Product and Service Offerings

31.6.3 Key Financial Summary

31.7 Eli Lilly and Company

31.7.1 Business Overview

31.7.2 Product and Service Offerings

31.7.3 Key Financial Summary

31.8 GlaxoSmithKline plc

31.8.1 Business Overview

31.8.2 Product and Service Offerings

31.8.3 Key Financial Summary

31.9 Mylan N.V.

31.9.1 Business Overview

31.9.2 Product and Service Offerings

31.9.3 Key Financial Summary

31.10 Bausch Health Companies Inc.

31.10.1 Business Overview

31.10.2 Product and Service Offerings

31.10.3 Key Financial Summary

31.11 Amgen Inc.

31.11.1 Business Overview

31.11.2 Product and Service Offerings

31.11.3 Key Financial Summary

31.12 Galderma S.A.

31.12.1 Business Overview

31.12.2 Product and Service Offerings

31.13 LEO Pharma A/S

31.13.1 Business Overview

31.13.2 Product and Service Offerings

31.13.3 Key Financial Summary

Chapter 32. Appendix

32.1 Abbreviations

32.2 Sources and References

32.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 LIST OF MAJOR PIPELINE DRUGS FOR PSORIASIS

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 PATENT EXPIRATION OF PSORIASIS DRUGS

TABLE 5 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 7 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 8 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 9 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 10 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019–2024)

TABLE 11 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 12 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY REGION, $M (2019–2024)

TABLE 13 GLOBAL PSORIASIS DRUGS MARKET REVENUE, BY REGION, $M (2021–2030)

TABLE 14 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 15 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 16 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 17 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 18 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019–2024)

TABLE 19 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 20 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 21 NORTH AMERICA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 22 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 23 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 24 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 25 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 26 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019–2024)

TABLE 27 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 28 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 29 EUROPE PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 30 APAC PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 31 APAC PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 32 APAC PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 33 APAC PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 34 APAC PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019–2024)

TABLE 35 APAC PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 36 APAC PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 37 APAC PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 38 LATAM PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 39 LATAM PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 40 LATAM PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 41 LATAM PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 42 LATAM PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019–2024)

TABLE 43 LATAM PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 44 LATAM PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 45 LATAM PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 46 MEA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 47 MEA PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 48 MEA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 49 MEA PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 50 MEA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019–2024)

TABLE 51 MEA PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2021–2030)

TABLE 52 MEA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 53 MEA PSORIASIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2021–2030)

TABLE 54 U.S. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 55 U.S. PSORIASIS DRUGS MARKET REVENUE, BY TYPE, $M (2021–2030)

TABLE 56 U.S. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2019–2024)

TABLE 57 U.S. PSORIASIS DRUGS MARKET REVENUE, BY MOA, $M (2021–2030)

TABLE 58 U.S. PSORIASIS DRUGS MARKET REVENUE, BY ROA, $M (2019&ndas